title: Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
abstract: This study investigates the differential gene expression profile of JAK2(V617F)-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied. Thirty-four genes were overexpressed in patients who did not respond to HU. Of these, some participate in proliferative pathways: MAPK, AKT, Src kinase (SFK), and JAK2 pathway. JAK2 allele burden was similar between groups of responders and nonresponder. A molecular fingerprint distinguishes JAK2(V617F)-positive MPN patients without response to HU treatment, with overexpression of JAK2, MAPK14, PIK3CA, and SFK genes.
authors.affiliation: Servicio de Hematología, Hospital Universitario 12 de Octubre, Avenida Córdoba s/n, 28041, Madrid, Spain.
authors.forename: Enriqueta
authors.initials: E
authors.lastname: Albizua
authors.forename: Miguel
authors.initials: M
authors.lastname: Gallardo
authors.forename: Santiago
authors.initials: S
authors.lastname: Barrio
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Rapado
authors.forename: Ana
authors.initials: A
authors.lastname: Jimenez
authors.forename: Rosa
authors.initials: R
authors.lastname: Ayala
authors.forename: Daniel
authors.initials: D
authors.lastname: Rueda
authors.forename: Beatriz
authors.initials: B
authors.lastname: Sanchez-Espiridion
authors.forename: Eulalia
authors.initials: E
authors.lastname: Puigdecanet
authors.forename: Blanca
authors.initials: B
authors.lastname: Espinet
authors.forename: Lourdes
authors.initials: L
authors.lastname: Florensa
authors.forename: Carles
authors.initials: C
authors.lastname: Besses
authors.forename: Joaquin
authors.initials: J
authors.lastname: Martinez-Lopez
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D005260:Female; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology* / Q000627:therapeutic use; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011086:Polycythemia / Q000188:drug therapy / Q000235:genetics; D011087:Polycythemia Vera / Q000188:drug therapy* / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D013920:Thrombocythemia, Essential / Q000188:drug therapy* / Q000235:genetics; D014157:Transcription Factors / Q000187:drug effects / Q000235:genetics; D055815:Young Adult; D019061:src-Family Kinases / Q000235:genetics*
chemical_list: D014157:Transcription Factors; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D019061:src-Family Kinases; D006918:Hydroxyurea